Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (ABT 1.18%) and DexCom (DXCM +0.97%) market devices that allow for convenient monitoring of blood sugar levels ...
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...
Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...
Healthcare stocks languished during most of 2019 as the markets fretted over political risks associated with the upcoming presidential election. But the sector picked up some steam in the last three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results